US-based Cordis, a leading interventional cardiovascular and endovascular technology developer and manufacturer, announced that it has acquired Swiss medical technology company MedAlliance for $1.135B (approximately €1.08B).
MedAlliance’s SELUTION SLR (Sustained Limus Release) programme, which includes a sustained sirolimus drug-eluting balloon (DEB), has been added as a new flagship product line that complements Cordis’ offerings. In return, Cordis will apply its sales, marketing, and distribution expertise to benefit MedAlliance’s customers.
Cordis’ customers will also gain from MedAlliance’s comprehensive clinical research and publications, especially those suffering from coronary and peripheral disease. These efforts will further strengthen Cordis’ commitment to delivering innovative patient solutions.
Shar Matin, Cordis CEO, says, “As a newly independent company, we are beyond proud to further our legacy of innovation and market disruption with MedAlliance and the first MicroReservoir sirolimus drug-eluting balloon, SELUTION SLR.”.